

Phar-East gathers over 700 Pharma & Biotech players across Asia

21 March 2019 | News

The 2019 edition brought over 120 expert speakers sharing on the latest trends and developments



On 18- 20 March 2019 after a successful 2018 debut, Phar-East once again brought together experts from Asian pharma & biotechs, big pharma, regulators, payers, technology innovators and more to share their expertise and chart Asia's path forward.

The 2019 edition brought over 120 expert speakers sharing on the latest trends and developments on 6 key themes: Immunotherapy, Pharma 4.0, Regulatory Affairs, Market Access and brand new for 2019, Clinical Trials and Biotech Investment.

The conference opened with a keynote session with Sir David Lane, Chief Scientist, A*STAR, Singapore on the topic of Going global and keeping it local: Is biotech innovation sustainable in Asia?

Sir David Lane is one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer. He will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.

After which Byung-Geon (BG) Rhee, CEO, SCM Lifesciences, Chairman, Council for Advanced Regenerative Medicine, Former President, Green Cross Corporation, South Korea shared more on the topic of Integrating Asia into the global era of innovative medicine.

There was also an interesting keynote panel on Pharma Trends: Women health as the next focus.

Overall, the 3-day event witnessed over 700 attendees and 40+ sponsors and exhibitors.